Lack of an effect of protease inhibitor use on glucose tolerance during pregnancy

Infectious Disease in Obstetrics and Gynecology

Volumn 10, Issue 4, 2002, Pages 187-191

  Dinsmoor, Mara J ^a,b   Forrest, Scott T ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Antiretroviral therapy; Combination therapy; Gestational diabetes; HIV infection in pregnancy; Hyperglycemia; Neonatal hypoglycemia

Indexed keywords

GLUCOSE; PROTEINASE INHIBITOR;

ADULT; ARTICLE; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; CONFIDENCE INTERVAL; CONTROLLED STUDY; FEMALE; FISHER EXACT TEST; GESTATION PERIOD; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE; GLUCOSE TOLERANCE TEST; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPOGLYCEMIA; NEWBORN; PRIORITY JOURNAL; RANK SUM TEST; SECOND TRIMESTER PREGNANCY; STUDENT T TEST;

ADULT; BLOOD GLUCOSE; CARBOHYDRATES; FEMALE; GESTATIONAL AGE; GLUCOSE TOLERANCE TEST; HIV INFECTIONS; HUMANS; INFANT, NEWBORN; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; PREGNANCY OUTCOME; PROTEASE INHIBITORS; VIRAL LOAD;

EID: 0036997364     PISSN: 10647449     EISSN: None     Source Type: Journal    
DOI: 10.1155/S1064744902000212     Document Type: Article

References (9)

1. Public Health Service Task Force recommendations for the use of antiretroviral drugs in pregnant women infected with HIV-1 for maternal health and for reducing perinatal HIV-1 transmission in the United States. Centers for Disease Control and Prevention. Morb Mortal Wkly Rep 1998;47(RR-2):1-30
2. Department of Health and Human Services and the Henry J. Kaiser Family Foundation, Panel on Clinical Practices for Treatment of HIV Infection. Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. HIV Clin Trials 2000;1:60-110
3. Carpenter CCJ, Cooper DA, Fischl MA, et al. Antiretroviral therapy in adults: updated recommendations of the International AIDS Society-USA Panel. J Am Med Assoc 2000;283:381-90
4. Carr A, Samaras K, Thorisdottir A, et al. Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyerlipidaemia, and diabetes mellitus: a cohort study. Lancet 1999; 353:2093-9.
5. Walli R, Herfort O, Michl GM,. et al. Treatment with protease inhibitors associated with peripheral insulin resistance and impaired oral glucose tolerance in HIV-1-infected patients. AIDS 1998;12:F167-73
6. Landon MB. Diabetes mellitus and other endocrine diseases. In Gabbe SG, Niebyl JR, Simpson JL, eds. Obstetrics: Normal and Problem Pregnancies, 3rd edn. New York: Churchill-Livingstone, 1996;1037-81
7. Connor EM, Sperling RS, Gelber R, et al. Reduction of maternal-infant transmission of human immunodeficiency virus type I with zidovudine treatment. N Engl J Med 1994;331:1173-80
8. Carr A, Samaras K, Chisholm DJ, Cooper DA. Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyerlipidaemia, and insulin resistance. Lancet 1998;351:1881-3
9. Hadigan C, Miller K, Corcoran C, et al. Fasting hyperinsulinemia and changes in regional body composition in human immunodeficiency virusinfected women. J Clin Endocrinol Metab 1999;84:1932-7